Related Experiment Video
Updated: Mar 14, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.8K
Drug limits heart damage in childhood chemotherapy
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|September 30, 2016
Insights
A new cardioprotective drug may prevent long-term heart damage in pediatric patients undergoing chemotherapy. This research offers hope for improving cardiovascular health outcomes in young cancer survivors.
Area of Science:
- Cardiology
- Pediatric Oncology
- Pharmacology
Background:
- Chemotherapy is a vital cancer treatment for children.
- Certain chemotherapy agents can cause long-term cardiotoxicity.
- This cardiac damage can lead to significant morbidity and mortality in pediatric cancer survivors.
Purpose of the Study:
- To investigate the potential cardioprotective effects of a novel drug.
- To evaluate the efficacy of this drug in mitigating chemotherapy-induced heart damage in pediatric patients.
Main Methods:
- The study involved a cohort of pediatric patients receiving specific chemotherapy regimens.
- Cardiovascular function was monitored before, during, and after treatment.
- Drug administration and its impact on cardiac biomarkers and function were assessed.
Main Results:
- Preliminary findings suggest a significant reduction in cardiac adverse events in the group receiving the cardioprotective drug.
- Key indicators of heart function remained more stable in patients treated with the drug.
- No major adverse effects of the cardioprotective drug were observed.
Conclusions:
- The cardioprotective drug demonstrates promising potential in preventing chemotherapy-related heart damage in children.
- Further research and clinical trials are warranted to confirm these findings and establish optimal treatment protocols.
- This intervention could significantly improve the long-term quality of life for pediatric cancer patients.
Abstract:
A cardioprotective drug could help prevent long-term heart damage in children who receive chemotherapy, researchers say.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
2.2K
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.2K
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
312
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:21Factors Affecting Drug Response: Overview
3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
01:29Drug Dosing: Infants and Children
677
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
677